Voorbeelden van het gebruik van Loading dose in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Steady- state plasma concentrations are attained by Day 6 at the 300 mg dose once daily after twice daily loading dose at Day 1.
Repso treatment starts with a‘loading dose' of 100 mg once a day for three days,
Loading Dose(IU)[(100- patient' s pre-treatment AT activity level in%)/ 2.28] x Body Weight in kg.
Based on a loading dose of 8 mg trastuzumab/kg body weight, or a subsequent 3-weekly dose of.
Side effects affecting the nervous system such as dizziness may be higher after a loading dose.
Arava treatment usually starts with a‘loading dose' of 100 mg once a day for three days,
Based on a loading dose of 4 mg trastuzumab/kg body weight, or a subsequent weekly dose of.
Loading dose(IU)[(100- patient's pre-treatment AT activity level in%)
In psoriatic arthritis: leflunomide therapy is started with a loading dose of 100 mg once daily for 3 days.
A loading dose should be considered in addition to a new maintenance dose when it is necessary to considerably increase sirolimus trough concentrations.
Arava treatment starts with a loading dose of 100 mg once a day for three days,
ORENCIA subcutaneous(SC) may be initiated with or without an intravenous(IV) loading dose.
The dose can be calculated utilizing the post-surgical AT activity in the loading dose formula above.
This staggered intake is the recommended administration for start of ticagrelor with a loading dose.
During clinical trials, a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose.
The steady state was achieved on the first day after a loading dose twice the daily maintenance dose. .
Due to the loading dose, steady state is reached after 2 Water.
3 hours for the loading dose.
A single 70 mg loading dose should be administered on Day-1,
Omission of the loading dose may decrease the risk of adverse events see section 5.1.